These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 8875582)
1. Consequences of hypogammaglobulinemia and steroid therapy in severe bronchopulmonary dysplasia. Wheeler W; Kurachek S; McNamara J; Fugate J; Hoogenhous N Pediatr Pulmonol; 1996 Aug; 22(2):96-100. PubMed ID: 8875582 [TBL] [Abstract][Full Text] [Related]
2. The use of intravenous immunoglobulin (IVIG) to prevent infections in bronchopulmonary dysplasia: report of a pilot study. Malik S; Giacoia GP; West K J Perinatol; 1991 Sep; 11(3):239-44. PubMed ID: 1919822 [TBL] [Abstract][Full Text] [Related]
3. Side effects and long-term follow-up of corticosteroid therapy in very low birthweight infants with bronchopulmonary dysplasia. Ferrara TB; Couser RJ; Hoekstra RE J Perinatol; 1990 Jun; 10(2):137-42. PubMed ID: 2358896 [TBL] [Abstract][Full Text] [Related]
4. [Prognosis factors in severe bronchopulmonary dysplasia. A retrospective study of 65 premature infants with bronchopulmonary dysplasia]. Hartmann JF; Beaufils F; Vervel C Arch Fr Pediatr; 1987; 44(6):423-31. PubMed ID: 3619581 [TBL] [Abstract][Full Text] [Related]
5. Restoration of humoral immunity after intravenous immunoglobulin replacement therapy in heart recipients with post-transplant antibody deficiency and severe infections. Carbone J; Sarmiento E; Del Pozo N; Rodriguez-Molina JJ; Navarro J; Fernandez-Yañez J; Palomo J; Villa A; Muñoz P; Fernandez-Cruz E Clin Transplant; 2012; 26(3):E277-83. PubMed ID: 22686951 [TBL] [Abstract][Full Text] [Related]
6. Hypogammaglobulinemia: Incidence, risk factors, and outcomes following pediatric lung transplantation. Robertson J; Elidemir O; Saz EU; Gulen F; Schecter M; McKenzie E; Heinle J; Smith E; Mallory G Pediatr Transplant; 2009 Sep; 13(6):754-9. PubMed ID: 19067916 [TBL] [Abstract][Full Text] [Related]
7. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. Oh W; Poindexter BB; Perritt R; Lemons JA; Bauer CR; Ehrenkranz RA; Stoll BJ; Poole K; Wright LL; J Pediatr; 2005 Dec; 147(6):786-90. PubMed ID: 16356432 [TBL] [Abstract][Full Text] [Related]
8. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia. Grimaldi M; Gouyon B; Michaut F; Huet F; Gouyon JB; Pediatr Infect Dis J; 2004 Dec; 23(12):1081-5. PubMed ID: 15626942 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. Aghamohammadi A; Moin M; Farhoudi A; Rezaei N; Pourpak Z; Movahedi M; Gharagozlou M; Nabavi M; Shahrokhi A FEMS Immunol Med Microbiol; 2004 Mar; 40(2):113-8. PubMed ID: 14987729 [TBL] [Abstract][Full Text] [Related]
10. [The combined effect of prenatal steroid prophylaxis, neonatal surfactant therapy and reduction of risk of complications from respiratory life support on survival rate of very low birthweight infants]. Görbe E; Jeager J; Kohalmi B; Patkós P; Cziniel M; Sassi L Orv Hetil; 2004 Jun; 145(23):1227-32. PubMed ID: 15264590 [TBL] [Abstract][Full Text] [Related]
11. Predisposition of infants with chronic lung disease to respiratory syncytial virus-induced respiratory failure: a vascular hypothesis. Carpenter TC; Stenmark KR Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S33-40. PubMed ID: 14730268 [TBL] [Abstract][Full Text] [Related]
12. Soluble vascular endothelial growth factor receptor 1 in tracheal aspirate fluid of preterm neonates at birth may be predictive of bronchopulmonary dysplasia/chronic lung disease. Hasan J; Beharry KD; Valencia AM; Strauss A; Modanlou HD Pediatrics; 2009 Jun; 123(6):1541-7. PubMed ID: 19482766 [TBL] [Abstract][Full Text] [Related]
13. Rehospitalization in the first year of life among infants with bronchopulmonary dysplasia. Smith VC; Zupancic JA; McCormick MC; Croen LA; Greene J; Escobar GJ; Richardson DK J Pediatr; 2004 Jun; 144(6):799-803. PubMed ID: 15192629 [TBL] [Abstract][Full Text] [Related]
14. The potential impact of substitutive therapy with intravenous immunoglobulin on the outcome of heart transplant recipients with infections. Carbone J; Sarmiento E; Palomo J; Fernandez-Yañez J; Muñoz P; Bouza E; Rodríguez-Molina J; Lanio N; Fernandez-Cruz E Transplant Proc; 2007 Sep; 39(7):2385-8. PubMed ID: 17889198 [TBL] [Abstract][Full Text] [Related]
15. Drug therapies in bronchopulmonary dysplasia: debunking the myths. Tin W; Wiswell TE Semin Fetal Neonatal Med; 2009 Dec; 14(6):383-90. PubMed ID: 19747890 [TBL] [Abstract][Full Text] [Related]
17. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China. Yang Y; Xu J; Li F; Zhu X Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409 [TBL] [Abstract][Full Text] [Related]
18. Populations at risk for developing respiratory syncytial virus and risk factors for respiratory syncytial virus severity: infants with predisposing conditions. Weisman L Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S33-7; discussion S37-9. PubMed ID: 12671450 [TBL] [Abstract][Full Text] [Related]
19. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Ehrenkranz RA; Walsh MC; Vohr BR; Jobe AH; Wright LL; Fanaroff AA; Wrage LA; Poole K; Pediatrics; 2005 Dec; 116(6):1353-60. PubMed ID: 16322158 [TBL] [Abstract][Full Text] [Related]
20. Time-related changes in steroid use and bronchopulmonary dysplasia in preterm infants. Yoder BA; Harrison M; Clark RH Pediatrics; 2009 Aug; 124(2):673-9. PubMed ID: 19620192 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]